Art. -Nr.: HY-123054

BTSA1

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

BTSA1 is a potent, high affinity and orally active BAX activator with an IC₅₀ of 250 nM and an EC₅₀ of 144 nM. BTSA1 binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.77%
CAS. Nr.: 314761-14-3
Formel: C₂₁H₁₄N₆OS₂
Molecular Weight:430.51

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

BTSA1 Chemical Structure

CAS. Nr.: 314761-14-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Bax

250 nM (IC₅₀)

Bax

144 nM (EC₅₀)

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	>20 μM Compound: 2; BTSA1	Antiproliferative activity against siRNA-induced BAX knock down human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against siRNA-induced BAX knock down human HeLa cells after 48 hrs by MTT assay	[PMID: 33021789]
HeLa	IC₅₀	0.81 μM Compound: 2; BTSA1	Synergistic antiproliferative activity against human HeLa cells assessed as assessed as reduction in cell viability after 48 hrs in presence of SAHA by MTT assay Synergistic antiproliferative activity against human HeLa cells assessed as assessed as reduction in cell viability after 48 hrs in presence of SAHA by MTT assay	[PMID: 33021789]
HeLa	IC₅₀	11.47 μM Compound: 2; BTSA1	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33021789]
L02	IC₅₀	54.2 μM Compound: 2; BTSA1	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33021789]

In Vitro

BTSA1 (5 μM; 6-24 hours; human AML cell lines) treatment reduced viability of all AML cell lines and displays substantial cell death activity within 6 hours^[1].
BTSA1 (2.5-10 μM; 6 hours; NB4 cells) treatment induces BAX translocation coincided with the release of cytochrome c from the mitochondria to the cytosol. Significant BAX mitochondrial translocation is induced in a BTSA1 dose-dependent manner^[1].
BTSA1 (0.15625-10 μM; 4-24 hours; OCI-AML3 cells) treatment induces dose-dependent caspase-3/7 activation in OCI-AML3 cells. Caspase-3/7 activation is monitored within 4-24 hours and maximal caspase-3/7 activation is detected in 4 hours^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assaysup>[1]

Cell Line:

Human AML cell lines<
Concentration:

5 μM
Incubation Time:

6 hours, 12 hours, 24 hours
Result:

Reduced viability of all AML cell lines. Displayed substantial cell death activity within 6 hours.

Western Blot Analysis^[1]

Cell Line:

NB4 cells
Concentration:

2.5 μM, 5 μM, 10 μM
Incubation Time:

6 hours
Result:

Significant BAX mitochondrial translocation was induced in a dose-dependent manner.

Apoptosis Analysis^[1]

Cell Line:

OCI-AML3 cells
Concentration:

0.15625 μM, 0.3125 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM
Incubation Time:

4 hours, 6 hours, 8 hours, 12 hours, 24 hours
Result:

Induced dose-dependent caspase-3/7 activation in OCI-AML3 cells. Caspase-3/7 activation was monitored within 4-24 hr and maximal caspase-3/7 activation was detected in 4 hr.

In Vivo

BTSA1 (10 mg/kg; intraperitoneal injection; every two days; NOD-SCID IL2Rγ null (NSG) mice) treatment significantly increases survival when compared to vehicle-treated mice. BTSA1 treatment induces significant suppression of leukemia growth^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD-SCID IL2Rγ null (NSG) mice (6-8 weeks old) with THP-1 cells^[1]
Dosage:

10 mg/kg
Administration:

Intraperitoneal injection; every two days
Result:

Significantly increased survival when compared to vehicle-treated mice.

Chemical Information

CAS. Nr. 314761-14-3
Appearance Solid
Molecular Weight 430.51
Formel C₂₁H₁₄N₆OS₂
Color Brown to reddish brown
SMILES

O=C(N(C1=NC(C2=CC=CC=C2)=CS1)N=C/3C4=CC=CC=C4)C3=N\NC5=NC=CS5
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Eur J Pharmacol

Characterization of mitochondrial dysfunction induced by BAX trigger site activator 1 in the ARPE-19 retinal pigment epithelial cell model. [Abstract]

2026 Jun 15:1027:178975. PMID: 42134759
Int J Mol Sci

Mitochondrial Trafficking of MLKL, Bak/Bax, and Drp1 Is Mediated by RIP1 and ROS which Leads to Decreased Mitochondrial Membrane Integrity during the Hyperglycemic Shift to Necroptosis. [Abstract]

2023 May 11;24(10):8609. PMID: 37239951

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (58.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3228 mL

11.6141 mL

23.2283 mL

5 mM

0.4646 mL

2.3228 mL

4.6457 mL

10 mM

0.2323 mL

1.1614 mL

2.3228 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Reyna DE, et al. Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. Cancer Cell. 2017 Oct 9;32(4):490-505.e10. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3228 mL	11.6141 mL	23.2283 mL	58.0707 mL
	5 mM	0.4646 mL	2.3228 mL	4.6457 mL	11.6141 mL
	10 mM	0.2323 mL	1.1614 mL	2.3228 mL	5.8071 mL
	15 mM	0.1549 mL	0.7743 mL	1.5486 mL	3.8714 mL
	20 mM	0.1161 mL	0.5807 mL	1.1614 mL	2.9035 mL
	25 mM	0.0929 mL	0.4646 mL	0.9291 mL	2.3228 mL
	30 mM	0.0774 mL	0.3871 mL	0.7743 mL	1.9357 mL
	40 mM	0.0581 mL	0.2904 mL	0.5807 mL	1.4518 mL
	50 mM	0.0465 mL	0.2323 mL	0.4646 mL	1.1614 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BTSA1

Orally Active Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Apoptosis Compound Library

Anti-Cancer Compound Library

Publications Citing Use of MedChemExpress (MCE) BTSA1

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BTSA1

Orally Active Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Apoptosis Compound Library

Anti-Cancer Compound Library

Publications Citing Use of MedChemExpress (MCE) BTSA1

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BTSA1 Related Classifications

HY-123054 Related Classifications